Norfen

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Norfen

Property Description
Active Ingredients Ethinyl Estradiol, Levonorgestrel
Form Oral Tablet
Pharmacological Class Combination Hormonal Contraceptive (CHC)
Common Use Pregnancy Prevention (Contraception)
Origin Synthetic

Norfen is a specific trade name for a prescription-only medication classified as a Combined Oral Contraceptive (COC). It falls into the broader pharmacological class of Combination Hormonal Contraceptives (CHC), signifying that it utilizes a blend of two distinct types of hormones to achieve its therapeutic function. This defines its identity as a systemic hormonal agent intended for regular, routine use by women.

What Type of Combination Hormonal Contraceptive is Norfen?

Norfen is a combination product that integrates a synthetic estrogen and a synthetic progestogen, making it a dual-acting birth control agent. The formulation harnesses the effects of two different steroid hormone types to regulate the female reproductive endocrine system. The integration of these two components is designed for the prevention of pregnancy.

Composition and Form: Synthetic Estrogen and Progestogen

The active ingredient composition of Norfen consists of the synthetic estrogen, Ethinyl Estradiol, and the synthetic progestogen, Levonorgestrel. Both compounds are laboratory-developed synthetic steroid hormones, not natural extracts. The drug is presented as an oral tablet and is administered via the oral route of administration, designed for systemic absorption and action throughout the body. The solid pharmaceutical excipients form the inert base of this tablet.

Primary Function: The Goal of Pregnancy Prevention

The general therapeutic purpose of Norfen is pregnancy prevention, or contraception. The combination of Ethinyl Estradiol and Levonorgestrel works through a multi-faceted physiological action, primarily by inhibiting the signals that trigger ovulation and simultaneously creating barriers to conception. This combined regulatory effect on the reproductive cycle is the defining function of the medication for those seeking long-term reversible contraception.

Regulatory References

  1. European Medicines Agency (EMA)

What side effects are possible with Norfen?

Possible side effects and safety information

The safety profile for Norfen, a combined hormonal contraceptive containing Ethinyl Estradiol and Levonorgestrel, is defined by regulatory agencies based on categorized frequency and system involvement. All documented safety information and adverse reactions are derived from official government-approved prescribing labels, such as the EMA Summary of Product Characteristics and FDA Prescribing Information.

Serious Adverse Reactions and Key Constraints

The most serious safety concerns documented for this class of medication relate to Thromboembolic Events, classified as rare but clinically significant. These include an increased risk of Venous Thromboembolism (VTE), such as Deep Vein Thrombosis and Pulmonary Embolism, and Arterial Thromboembolism (ATE), including Stroke and Myocardial Infarction. The risk of VTE is noted to be highest during the first year of initial use or upon restarting after a break of four weeks or more.

The medication is contraindicated by regulatory documents in women over age 35 who smoke due to the significantly elevated risk of serious cardiovascular events. Contraindications also apply to individuals with a history of thromboembolic disorders, severe hepatic impairment, or migraines with aura.

Common Adverse Reactions and Time Patterns

Adverse reactions classified as Very Common or Common in official labeling primarily involve the gastrointestinal, nervous, and reproductive systems. These frequently documented effects include Headache, Nausea/Vomiting, Breast Tenderness or Pain, Mood Changes, and Weight Changes.

Intermenstrual bleeding (spotting) is explicitly noted as a very common effect that is often observed to be more frequent during the first three months of treatment, aligning with documented exposure-related patterns.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documentation states that acute overdose of Norfen (Ethinyl Estradiol and Levonorgestrel) is not expected to be life-threatening. This profile is based on evidence that serious undesirable effects have not been reported following the acute ingestion of large doses.

Documented Overdose Manifestations

The most common regulator-documented clinical signs and symptoms of acute overdose involve the gastrointestinal and reproductive systems:

  • Nausea and Vomiting
  • Withdrawal bleeding (vaginal bleeding), which may occur several days after the event

Required Emergency Action

Regardless of the low acute toxicity profile, immediate actions are mandated by official guidance. Patients must seek immediate medical attention for any suspected overdose. It is required to contact a Poison Control Center or local emergency services (e.g., call the local emergency number) immediately following the event.

Management and Monitoring

No specific antidote is known for Norfen overdose. Treatment is restricted to symptomatic and supportive measures to manage documented clinical manifestations. Healthcare professionals may require monitoring of vital signs and laboratory tests. Inducing vomiting should not be performed unless specifically instructed by poison control personnel or a healthcare provider.

Therapeutic Uses of Norfen

What Norfen Treats: Main Uses and Benefits

Norfen, a combined oral contraceptive (COC), is used across domains where additional symptomatic support is needed, primarily within reproductive health. The medication is applied in clinical situations involving the management of specific physiological symptoms.

The essential therapeutic benefit of Norfen provides supportive fertility control and pregnancy prevention. It is used to maintain intentional reproductive regulation for women of reproductive potential. This application helps manage the factors related to the risk of unplanned pregnancy, assisting with reproductive health stability.

The medication is utilized across multiple therapeutic domains, including supportive fertility control and the symptomatic management of heavy periods, painful periods, and mild to moderate acne.

The medication is also relevant for addressing symptom clusters that may be disruptive during the menstrual cycle. It is used for managing heavy menstrual bleeding (menorrhagia) and is relevant for addressing painful menstrual cramps (dysmenorrhea), which contributes to more predictable, regular menstrual cycles. This application is intended to support patients by managing physical distress during the cycle.

The medication is applicable in clinical settings involving hormone-sensitive conditions. It may be part of symptomatic management for the pain and bleeding patterns in conditions like endometriosis and is used to help manage the symptomatic manifestations of mild to moderate acne in certain patients.


Quick Fact: Supportive Management for Menstrual Symptoms

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Norfen is a combination oral contraceptive whose eligibility is strictly defined by regulatory authorities to manage the risks associated with estrogen and progestin, primarily thromboembolism.

Populations for Whom Use is Contraindicated

The medicine must not be used by females with a high risk of arterial or venous thrombotic diseases, including a current or history of Deep Vein Thrombosis, Pulmonary Embolism, Stroke, or Coronary Artery Disease. Use is also prohibited for:

  • Females over age 35 who smoke.
  • Females with uncontrolled hypertension (severe high blood pressure).
  • Females with liver tumors, severe (decompensated) cirrhosis, or acute viral hepatitis.
  • Females with current or a history of breast cancer (or other estrogen-sensitive malignancies).
  • Females with migraine headaches with focal neurological symptoms (migraine with aura).
  • Females with known or suspected pregnancy or undiagnosed abnormal genital bleeding.

Eligibility Restrictions

  • Postpartum and Lactation: Use is not recommended in the immediate postpartum period or while exclusively breastfeeding, as this may affect milk production.
  • Surgery/Immobilization: The medicine should be discontinued at least four weeks before and through two weeks after major surgery or during prolonged immobilization, due to the increased risk of blood clots.
  • Age Groups: Use is not indicated in pre-menarcheal females and is not intended for use in post-menopausal women.

These official regulatory criteria define who can and cannot use the medicine under standard labeled conditions.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Norfen (Ethinyl Estradiol/Levonorgestrel) specifies several required constraints based on documented pharmacokinetic and pharmacodynamic interactions.

Contraindicated Combinations: Co-administration is formally contraindicated with certain Hepatitis C Virus (HCV) drug regimens, specifically Ombitasvir/Paritaprevir/Ritonavir (with or without Dasabuvir), due to the documented risk of significant Alanine Transaminase (ALT) elevations. The combination with Oral Tranexamic Acid is also prohibited due to documented pharmacodynamic synergism leading to an increased risk of thrombotic events. Fezolinetant is contraindicated because the Ethinyl Estradiol component is documented to increase its plasma concentration.

Exposure Alterations and Metabolic Factors: Substances documented as hepatic enzyme inducers (e.g., Rifampin, Carbamazepine, Phenytoin) may cause a decrease in systemic exposure of Norfen's components, which can diminish effectiveness. Conversely, some enzyme inhibitors and other drugs (e.g., Itraconazole, Atorvastatin, Ascorbic Acid) are documented to increase systemic exposure of the Ethinyl Estradiol component. The herbal product St. John's wort is listed as an enzyme inducer that may also reduce plasma concentrations.

Timing and Population Constraints: The absorption of Norfen is significantly reduced by the bile acid sequestrant Colesevelam, necessitating that it be administered four or more hours apart to attenuate the reduction in systemic exposure. Furthermore, the use of Norfen is formally contraindicated in women over 35 years of age who smoke due to the officially documented heightened risk of serious cardiovascular events within this specific population.

Mechanism of Action

How Norfen Works

Norfen acts by modulating activity within specific receptor and enzyme systems. Its mechanism is targeted and involves several precise steps at the cellular and systemic level.

Specific Target Engagement

Norfen initiates its action by selectively engaging a specific receptor or enzyme system . This interaction functions as the primary mechanistic event, either inhibiting a component's activity or initiating a suppressive response. This early, precise molecular step focuses the drug’s action onto a foundational component of the pathway.

Modulation of Signaling Cascades

Following target engagement, Norfen effectively alters the signal transduction dynamics within defined neural or humoral pathways. The drug suppresses excessive signaling that may otherwise escalate, modifying early molecular steps that shape the systemic outcome. This targeted pathway interference influences the activation threshold of downstream effectors.

Altering Physiological Dynamics

The drug's activity affects feedback mechanisms within the targeted systems. The mechanism involves suppression of excessive mediator activity, which alters the dynamics of overactive physiological responses. These physiological adjustments reflect the drug’s overall pharmacological action.

Dosage and Administration Information

How to Use Norfen

The usage of Norfen, a combination hormonal contraceptive, is defined by a routine and cyclic administration schedule. This medication is administered via the oral route as a monophasic tablet, with each active dose containing 0.15 mg of Levonorgestrel and 0.03 mg of Ethinyl Estradiol. The dosing regimen is fundamentally structured around taking one tablet daily at the same time each day to maintain hormonal consistency.


Official Usage Patterns

The most common use pattern involves a 28-day cycle, consisting of 21 consecutive days of active tablets followed by 7 days of inactive or hormone-free tablets. The tablets must be swallowed whole and taken strictly in the sequence indicated on the packaging, which is essential for maintaining the intended dose progression. The administration timing is independent of meals, allowing for flexibility in intake, provided the daily consistency is maintained.


Administration Requirements and Adjustments

Instruction Detail
Route of Administration Oral
Frequency Pattern Daily, cyclic use
Age-Group Rule Approved for postmenarchal females only (not indicated for postmenopausal use)
Procedural Condition Tablets must be taken in the sequential order printed on the pack

Standard protocols provide guidance for the handling of procedural errors. Specific instructions dictate the steps for a missed active dose, which may involve taking two tablets on the same day and the temporary use of a non-hormonal back-up method. Similar procedural guidance applies if vomiting or severe diarrhea occurs within a few hours of taking an active tablet, as these conditions may interfere with adequate absorption.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Norfen

Evidence for use in Pregnancy Prevention (Contraception)

Norfen, which contains Ethinyl Estradiol and Levonorgestrel, was studied for outcomes related to reproductive regulation. This evidence base relies on research that spans decades, including large-scale, multi-center Randomized Controlled Trials (RCTs) and very large Prospective Observational Studies. Research primarily examined the measurement of the pregnancy rate over a defined period, often expressed as the Pearl Index. Studies also monitored outcomes related to continuation rates and adherence to the regimen.

While the evidence for its primary studied function is extensive, data show patterns related to measured outcomes that can be influenced by consistency of use. The long-term effects are not fully established through controlled trials, though large-scale observational data contributes to the broader evidence landscape regarding continuation and long-term surveillance.


Evidence for use in Symptomatic Menstrual Management

This combination was evaluated in studies exploring short-term symptom changes related to the menstrual cycle. The evidence base includes RCTs and systematic reviews, which were used in research exploring symptom variability over defined time intervals.

  • Heavy Menstrual Bleeding: Studies examined patients with heavy menstrual bleeding and focused on objective outcomes monitoring physiological strain or stress, such as measured blood loss volume. Trials report how symptoms changed in the observed populations over follow-up periods that were generally short-to-intermediate term. Data for certain groups remain insufficient.

  • Painful Menstrual Cramps: Studies primarily examined patient-reported outcomes describing perceived discomfort, such as change in pain severity scores. Comparative evidence is lacking for some specific dosage forms, and follow-up durations were limited in many of the core pain trials, often concluding after only a few menstrual cycles.


Evidence for use in Mild to Moderate Acne

This combination was observed in high-quality Randomized, Double-Blind, Placebo-Controlled Clinical Trials to assess its use in studies examining symptom intensity or variability related to skin appearance. Research describes changes measured during the study period in skin appearance, as assessed by clinicians using standardized scales. Sample sizes were modest in some specific formulation trials, and there is limited information for long-term outcomes regarding the sustained effects after treatment is stopped.


The Landscape of Remaining Research Uncertainty

The evidence landscape shows that while the primary use has been evaluated across extensive studies, findings were mixed regarding specific dosage forms for secondary uses. Research does not determine whether an individual will respond similarly, and this research provides insight into short-term changes, but long-term effects are not fully established.

Key Studies & References

  1. Combined Oral Contraceptives
  2. Levonorgestrel and Ethinyl Estradiol: Drug Information

Frequently Asked Questions (FAQ)

Common questions about Norfen (FAQ)


Q: How quickly does Norfen start working?

Official product information indicates that the body requires at least seven days of consistent use to reach the intended level of pregnancy prevention. For this reason, official protocols describe the use of a non-hormonal back-up method during the first seven days of administration.

Q: How long do the effects of Norfen last?

The effectiveness of Norfen is dependent on consistent, daily administration. Official regulatory information describes that the dose is taken every 24 hours to maintain the necessary hormonal consistency for reproductive regulation.

Q: Can Norfen affect sleep patterns?

Official documents list difficulty in sleeping as a documented adverse effect that has been reported by patients taking this medication.

Q: Is it okay to take Norfen with caffeine?

Regulatory documents state that the ethinyl estradiol component in Norfen may increase the blood levels of caffeine in the body. This alteration in exposure may potentially increase the risk or severity of experiencing caffeine-related side effects.

Q: What foods should I avoid while using Norfen?

Official drug interaction studies have documented a potential interaction between the ethinyl estradiol component and grapefruit juice. Regulatory guidance describes avoiding the regular consumption of grapefruit juice while taking the medication.

Q: Can people with kidney issues use Norfen?

According to official regulatory information, there have been no formal clinical studies specifically evaluating how kidney (renal) disease affects the disposition or processing of Norfen's active components.

Q: Where can I find the patient information leaflet for Norfen?

The Patient Information Leaflet (PIL) is part of the approved regulatory package for Norfen. This document can typically be accessed directly through the FDA DailyMed website or can be obtained from the healthcare provider who prescribed the medicine.

Q: Is Norfen a controlled substance?

Official documentation from the US Drug Enforcement Administration (DEA) indicates that this combination drug is not classified as a federally controlled substance. It is not considered to have abuse or dependency potential under regulatory guidelines.

Q: Is Norfen available in generic form?

Official FDA records confirm that the active ingredients in Norfen (Ethinyl Estradiol and Levonorgestrel) are widely available in various FDA-approved generic formulations.

Q: What should I do if I experience a severe reaction to Norfen?

If serious symptoms occur while taking Norfen, such as sudden chest pain, slurred speech, or signs that suggest a blood clot, official instructions describe stopping the medication immediately. Regulatory guidance indicates that emergency medical treatment should be sought for these reactions.

Q: Is Norfen habit-forming?

According to official regulatory body assessments, there is no evidence that this medication or its active components have an abuse potential. It is not classified as a habit-forming or controlled substance.

Q: What happens when you stop taking Norfen?

Studies and official documents indicate that fertility and the natural menstrual cycle typically return quickly after the medication is discontinued. This is attributed to the drug's short half-life and rapidly reversible physiological action.

Q: Is Norfen used for fever reduction?

Official regulatory documents and the Summary of Product Characteristics confirm that the approved therapeutic indications for Norfen do not include the reduction or management of fever.

Q: What is the difference between the daily maximum and the individual dose of Norfen?

Regulatory prescribing information defines the individual dose and the maximum daily dose for Norfen as the same amount: one tablet daily. This specified administration schedule is necessary to maintain the effectiveness of the drug over the 28-day cycle.

Q: What does 'contraindication' mean in relation to Norfen?

In official medical terms, a contraindication is a health condition or symptom that makes a specific treatment inadvisable. Regulatory bodies use this term to identify patient groups for whom taking Norfen may be harmful or carry an unacceptable level of risk.

Q: Does Norfen interact with birth control pills?

Norfen itself is classified as a combination oral contraceptive (birth control pill). Official documentation states that it is not administered in combination with other hormonal birth control agents due to the potential for overexposure to hormones and hormonal imbalance.

Q: What are the signs of an overdose of Norfen?

According to official drug information, symptoms that may occur in the event of an overdose typically include nausea, vomiting, and in women, the potential for vaginal bleeding.

Q: Are there any long-term side effects associated with Norfen?

Formal studies defining the effects of long-term use are limited, but large-scale observational data contributes to the broader evidence base. Long-term risks associated with this drug class include an increased risk of serious cardiovascular events.

Q: Why does the packaging say Norfen has a risk of [Specific Rare Side Effect]?

Regulatory agencies require warnings for serious, though rare, risks to be prominently displayed in labeling, often in a Boxed Warning. This procedure is designed to ensure all patients and prescribers are fully informed of potential dangers, such as the risk of thromboembolic events, prior to use.

Q: Is it normal to feel a little dizzy after starting Norfen?

Official adverse reaction reports indicate that dizziness has been reported as a common side effect in clinical studies of this drug combination. Dizziness is described in official documents as a documented reaction.

Q: What kind of studies have been done on Norfen for long-term use?

Research focusing on the sustained effects of Norfen primarily relies on large-scale, long-term Prospective Observational Studies for monitoring safety and continuation. Controlled trials often have limited follow-up duration, making observational data important for long-term surveillance.

Q: Can Norfen be split or crushed?

Official product information describes that the tablets are administered exactly as directed and are swallowed whole. This administration requirement is specified to ensure the drug's dose is delivered and absorbed as intended by the manufacturer.

Q: Are there any specific lifestyle changes recommended while taking Norfen?

The most significant lifestyle constraint is explicitly stated in the regulatory documentation regarding smoking. The medicine is contraindicated for women over 35 years of age who smoke because this combination significantly heightens the risk of serious cardiovascular events.

Q: How reliable is the evidence supporting Norfen's use?

Evidence for Norfen's primary use (contraception) is extensive and relies on both randomized trials and large observational studies. However, official documents note that findings were mixed regarding specific dosage forms for secondary uses, and long-term effects are not fully established.

How should Norfen be stored and disposed of?

How to Store and Dispose of Norfen

Norfen (Ethinyl Estradiol/Levonorgestrel) must be stored strictly according to official regulatory guidelines to maintain its stability.

Official Storage Requirements

Item Requirement (Official Regulatory Standard)
Temperature Controlled Room Temperature (20°C to 25°C / 68°F to 77°F).
Protection Protect from excessive heat and moisture; do not freeze or refrigerate.
Container Store in the original container or blister pack.
Child Safety Keep out of the sight and reach of children.

Disposal Instructions

Unused or expired Norfen should be disposed of through a medicine take-back program, which is the preferred method. If a take-back program is unavailable, tablets may be mixed with an undesirable substance and discarded in the household trash. Do not flush Norfen down the toilet or pour it down a sink.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Norfen found in:

A-Z Index: